NZ626742A - Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer - Google Patents

Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer

Info

Publication number
NZ626742A
NZ626742A NZ626742A NZ62674213A NZ626742A NZ 626742 A NZ626742 A NZ 626742A NZ 626742 A NZ626742 A NZ 626742A NZ 62674213 A NZ62674213 A NZ 62674213A NZ 626742 A NZ626742 A NZ 626742A
Authority
NZ
New Zealand
Prior art keywords
inhibitor
egfr
clusterin
treat cancer
egfr inhibitor
Prior art date
Application number
NZ626742A
Other languages
English (en)
Inventor
Gilles Bernard Tremblay
Elisabeth Viau
Mario Filion
Original Assignee
Alethia Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alethia Biotherapeutics Inc filed Critical Alethia Biotherapeutics Inc
Publication of NZ626742A publication Critical patent/NZ626742A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ626742A 2012-02-22 2013-02-22 Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer NZ626742A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261601786P 2012-02-22 2012-02-22
PCT/CA2013/000167 WO2013123588A1 (en) 2012-02-22 2013-02-22 Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer

Publications (1)

Publication Number Publication Date
NZ626742A true NZ626742A (en) 2016-06-24

Family

ID=49004878

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ626742A NZ626742A (en) 2012-02-22 2013-02-22 Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer

Country Status (11)

Country Link
US (1) US9822170B2 (enExample)
EP (1) EP2817028A4 (enExample)
JP (1) JP2015512877A (enExample)
CN (1) CN104159611A (enExample)
AU (1) AU2013224591A1 (enExample)
BR (1) BR112014020756A2 (enExample)
CA (1) CA2862739A1 (enExample)
EA (1) EA201491568A1 (enExample)
MX (1) MX2014010164A (enExample)
NZ (1) NZ626742A (enExample)
WO (1) WO2013123588A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2928846A1 (en) 2009-11-24 2011-06-03 Alethia Biotherapeutics Inc. Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
CA2862739A1 (en) 2012-02-22 2013-08-29 Alethia Biotherapeutics Inc. Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer
JP6464436B2 (ja) 2014-02-07 2019-02-06 アジュ ユニバーシティー インダストリー−アカデミック コーオペレイション ファウンデーションＡｊｏｕ Ｕｎｉｖｅｒｓｉｔｙ Ｉｎｄｕｓｔｒｙ−Ａｃａｄｅｍｉｃ Ｃｏｏｐｅｒａｔｉｏｎ Ｆｏｕｎｄａｔｉｏｎ 受容体共役タンパク質キナーゼ−３（ｒｉｐ３）発現促進剤を有効成分として含む抗癌補助用組成物、受容体共役タンパク質キナーゼ−３（ｒｉｐ３）の発現を促して抗癌剤感受性を増進させる抗癌補助剤のスクリーニング方法及び抗癌剤感受性のモニターリング方法
WO2016098041A1 (en) 2014-12-18 2016-06-23 Saarum Sciences Private Ltd Establishment and use of an in vitro platform for emt
CN105987997B (zh) * 2015-01-30 2017-12-29 江苏众红生物工程创药研究院有限公司 人组织激肽释放酶1荧光定量检测试纸卡
CN105988004B (zh) * 2015-01-30 2017-12-29 江苏众红生物工程创药研究院有限公司 人组织激肽释放酶1胶体金定量检测试纸卡
CN109912716B (zh) * 2017-12-13 2022-08-23 凯惠科技发展(上海)有限公司 一种egfr抗体及其制备方法和应用
CN113474012B (zh) * 2019-01-25 2023-09-08 湖南远泰生物技术有限公司 Epcam抗体和epcam-car-t细胞
CN114249832B (zh) * 2020-09-24 2023-11-10 博源润生医药（杭州）有限公司 一种靶向cpsg4的人源化嵌合抗原受体及表达该嵌合抗原受体的免疫效应细胞及其应用
EP4329801A4 (en) * 2021-04-27 2025-05-14 Alethia Biotherapeutics Inc. Method for allowing immune cells infiltration in tumors
EP4475885A4 (en) * 2022-02-07 2026-02-18 Alethia Biotherapeutics Ulc POLYTHERAPY INTENDED FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
CN117903305B (zh) * 2023-12-05 2024-08-27 南京欧凯生物科技有限公司 针对雌二醇的单克隆抗体、基于其的检测试剂及其应用

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3933850A1 (de) 1989-10-06 1991-04-18 Schering Ag Zytolyse-inhibitor (zli), eine diese blutplasmaprotein kodierende dna-sequenz, sowie ein plasmid, ein wirtsorganismus und ein verfahren zur gewinnung dieses proteins
ATE204299T1 (de) 1993-03-05 2001-09-15 Bayer Ag Humane monoklonale anti-tnf alpha antikörper
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6383808B1 (en) 2000-09-11 2002-05-07 Isis Pharmaceuticals, Inc. Antisense inhibition of clusterin expression
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
WO2000034469A1 (en) 1998-12-11 2000-06-15 The Research Foundation Of State University Of New York At Albany Compositions and methods for altering cell migration
US6900187B2 (en) 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
NZ513757A (en) 1999-02-26 2004-12-24 Univ British Columbia Antisense oligonucleotides to inhibit TRPM-2 expression and delay androgen independance in prostatic tumour cells
EP1179541B1 (en) 1999-04-28 2004-06-16 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting VEGF
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US7291714B1 (en) 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US20050208558A1 (en) 1999-10-19 2005-09-22 Applera Corporation Detection kits, such as nucleic acid arrays, for detecting the expression or 10,000 or more Drosophila genes and uses thereof
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
CA2402293A1 (en) 2000-03-07 2001-09-13 Hyseq, Inc. Novel nucleic acids and polypeptides
AU2001253140A1 (en) 2000-04-03 2001-10-15 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Tumor markers in ovarian cancer
US6812339B1 (en) 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
JP2004521627A (ja) 2001-02-09 2004-07-22 インサイト・ゲノミックス・インコーポレイテッド 細胞増殖、細胞分化および細胞死に関連するタンパク質
CA2443644A1 (en) 2001-04-04 2003-01-16 Elan Corporation, Plc Genetic analysis of peyers's patches and m cells and methods and compositions targeting peyer's patches and m cell receptors
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
US20030134301A1 (en) 2001-07-27 2003-07-17 Brooksbank Robert Alan Identification and use of molecules implicated in pain
AU2002324700A1 (en) 2001-08-14 2003-03-03 Bayer Ag Nucleic acid and amino acid sequences involved in pain
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US20070082337A1 (en) 2004-01-27 2007-04-12 Compugen Ltd. Methods of identifying putative gene products by interspecies sequence comparison and biomolecular sequences uncovered thereby
WO2003054152A2 (en) 2001-12-10 2003-07-03 Nuvelo, Inc. Novel nucleic acids and polypeptides
WO2003062421A1 (en) 2002-01-17 2003-07-31 The University Of British Columbia Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same
WO2003080640A1 (en) 2002-03-07 2003-10-02 Ludwig Institute For Cancer Research Lymphatic and blood endothelial cell genes
AU2003210060B2 (en) 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
WO2004005934A2 (en) 2002-07-04 2004-01-15 Oxford Glycosciences (Uk) Ltd Toxicity markers
KR101117673B1 (ko) 2002-08-21 2012-03-07 더 유니버시티 오브 브리티쉬 콜롬비아 암-관련 단백질을 표적으로 하는 알엔에이아이 프로브
US7285541B2 (en) 2002-08-21 2007-10-23 The University Of British Columbia Treatment of melanoma by reduction in clusterin levels
WO2004028479A2 (en) 2002-09-25 2004-04-08 Genentech, Inc. Nouvelles compositions et methodes de traitement du psoriasis
US20050048490A1 (en) 2002-09-26 2005-03-03 Incyte Corp. Proteins associated with cell growth, differentiation, and death
US8722872B2 (en) 2002-10-02 2014-05-13 The University Of British Columbia Compositions and methods for treatment of prostate and other cancers
CA2500687A1 (en) 2002-10-02 2004-04-15 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
DE10256900A1 (de) 2002-11-29 2004-06-24 Nemod Immuntherapie Ag Tumorspezifische Erkennungsmoleküle
US20040146921A1 (en) 2003-01-24 2004-07-29 Bayer Pharmaceuticals Corporation Expression profiles for colon cancer and methods of use
WO2005049806A2 (en) 2003-03-14 2005-06-02 Nuvelo, Inc. Novel nucleic acids and polypeptides
EP1610810A2 (en) 2003-03-28 2006-01-04 Applied Research Systems ARS Holding N.V. Use of clusterin for the treatment and/or prevention of peripheral neurological diseases
US20050255114A1 (en) 2003-04-07 2005-11-17 Nuvelo, Inc. Methods and diagnosis for the treatment of preeclampsia
CA2520518A1 (en) 2003-04-18 2004-10-28 The University Of British Columbia Method for treatment of angiogenic disorders
US20040220131A1 (en) 2003-04-18 2004-11-04 The University Of British Columbia Method for treatment of cancerous angiogenic disorders
JP2007506442A (ja) * 2003-05-30 2007-03-22 ゲノミック ヘルス， インコーポレイテッド Ｅｇｆｒ阻害薬への応答に関する遺伝子発現マーカー
WO2005014849A2 (en) 2003-07-03 2005-02-17 Euro-Celtique, S.A. Genes associated with responses to neuropathic pain
CA2533803A1 (en) 2003-07-29 2005-02-10 Bristol-Myers Squibb Company Biomarkers of cyclin-dependent kinase modulation
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
AU2004272607B2 (en) 2003-09-11 2008-11-06 Cornerstone Therapeutics Inc. Monoclonal antibodies against HMGB1
EP1708961B1 (en) 2003-12-04 2011-03-09 Abbott Biotherapeutics Corp. Anti-ip-10 antibodies
AT412785B (de) 2003-12-04 2005-07-25 Kungl Andreas J Dr Gag-bindungsproteine
GB0329254D0 (en) 2003-12-17 2004-01-21 Univ Manchester Treatment of viral infections
GB0329958D0 (en) 2003-12-24 2004-01-28 Univ Manchester Treatment of viral infections
US7309487B2 (en) 2004-02-09 2007-12-18 George Inana Methods and compositions for detecting and treating retinal diseases
EP1713502A1 (de) * 2004-02-12 2006-10-25 MERCK PATENT GmbH Hochkonzentrierte, flüssige formulierungen von anti-egfr-antikörpern
ITRM20040098A1 (it) 2004-02-25 2004-05-25 Univ Roma Anticorpi oligoclonali anticlasterina per la diagnosi di neoplasie e la predizione del loro grado di malignita', metodo diagnostico e kit relativi.
US8710020B2 (en) 2004-04-02 2014-04-29 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
KR20070049637A (ko) 2004-07-09 2007-05-11 트리패스 이미징, 인코포레이티드 난소 질환 검출 방법 및 조성물
GB0421639D0 (en) 2004-09-29 2004-10-27 Proteome Sciences Plc Methods and compositions relating to alzheimer's disease
WO2006037604A1 (en) 2004-10-01 2006-04-13 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Novel antibodies directed to the mammalian eag1 ion channel protein
SI1814595T1 (sl) 2004-11-23 2014-06-30 The University Of British Columbia Zdravljenje raka s kombinacijo sredstva, ki moti EGF signalno pot, in oligonukleotida, ki zniĹľuje nivoje klusterina
WO2006081430A2 (en) 2005-01-27 2006-08-03 Five Prime Therapeutics, Inc. Leader sequences for directing secretion of polypeptides and methods for production thereof
US7883858B2 (en) 2005-01-27 2011-02-08 Institute For Systems Biology Methods for identifying and monitoring drug side effects
WO2006089586A1 (en) 2005-02-23 2006-08-31 Medizinische Universität Graz Use of a compound with clusterin activity for the treatment of diseases associated with the deposition of abnormal proteins
WO2006096653A2 (en) 2005-03-04 2006-09-14 Biogen Idec Ma Inc. Methods of humanizing immunoglobulin variable regions through rational modification of complementarity determining residues
US20080307537A1 (en) 2005-03-31 2008-12-11 Dana-Farber Cancer Institute, Inc. Compositions and Methods for the Identification, Assessment, Prevention, and Therapy of Neurological Diseases, Disorders and Conditions
WO2006113671A2 (en) 2005-04-15 2006-10-26 Oncomethylome Sciences, S.A. Methylation markers for diagnosis and treatment of cancers
WO2007022248A2 (en) 2005-08-16 2007-02-22 Sloan Kettering Institute For Cancer Research Methods of detection of cancer using peptide profiles
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
ES2543341T3 (es) 2005-09-13 2015-08-18 National Research Council Of Canada Métodos y composiciones para modular la actividad de células tumorales
KR101126423B1 (ko) 2005-10-21 2012-07-11 카탈리스트 바이오사이언시즈, 인코포레이티드 보체 활성화를 억제하는 변형된 프로테아제
US7972802B2 (en) 2005-10-31 2011-07-05 University Of Washington Lipoprotein-associated markers for cardiovascular disease
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
EP1963534A2 (en) 2005-12-19 2008-09-03 Genizon Biosciences Inc. Genemap of the human gene associated with crohn's disease
CA2634072A1 (en) 2005-12-21 2007-06-28 Universite De Montreal Markers for memory t cells and uses thereof
KR100679173B1 (ko) 2006-02-28 2007-02-06 주식회사 바이오인프라 위암 진단용 단백질 마커 및 이를 이용한 진단키트
MY169492A (en) 2006-03-23 2019-04-15 Bioarctic Neuroscience Ab Improved protofibril selective antibodies and the use thereof
US20080026485A1 (en) 2006-04-18 2008-01-31 Wolfgang Hueber Antibody profiling for determination of patient responsiveness
CA2660286A1 (en) 2006-08-09 2008-02-21 Homestead Clinical Corporation Organ-specific proteins and methods of their use
EP2087152B1 (en) 2006-10-27 2015-03-11 Walfish, Paul Endometrial biomarkers
WO2008085024A1 (en) 2007-01-12 2008-07-17 Erasmus University Medical Center Rotterdam Identification and detection of peptides relating to specific disorders
GB0703652D0 (en) 2007-02-26 2007-04-04 Univ Bradford Method for the allosteric modulation of beta1 integrin
WO2009006382A1 (en) 2007-07-02 2009-01-08 Purdue Research Foundation Detection of glycopeptides and glycoproteins for medical diagnostics
WO2009034562A2 (en) 2007-09-11 2009-03-19 Dublin City University A method of assessing lung squamous cell carcinoma status in an individual
US8617877B2 (en) 2007-11-02 2013-12-31 The Johns Hopkins University Cardiac stem cell and myocyte secreted paracrine factors
US7923253B2 (en) 2007-11-05 2011-04-12 Battelle Memorial Institute Method for identifying type I diabetes mellitus in humans
EP2071336A1 (en) * 2007-12-13 2009-06-17 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Serum proteomic for finding diagnostic markers and for monitoring therapeutical intervention in treatment of hepatocellular carcinoma
WO2009117030A2 (en) 2007-12-19 2009-09-24 Macrogenics, Inc. Improved compositions for the prevention and treatment of smallpox
EP2080812A1 (en) 2008-01-18 2009-07-22 Transmedi SA Compositions and methods of detecting post-stop peptides
WO2009093246A2 (en) 2008-01-22 2009-07-30 Compugen Ltd. Novel clusterin derived peptide
WO2009116860A1 (en) 2008-03-17 2009-09-24 Vereniging Het Nederlands Kanker Instituut Markers providing prognosis of metastasis among cancer patients
KR101110758B1 (ko) 2008-06-02 2012-02-15 경북대학교 산학협력단 뇌졸중 표적용 펩티드 및 이의 용도
US8148088B2 (en) 2008-07-18 2012-04-03 Abgent Regulation of autophagy pathway phosphorylation and uses thereof
WO2010030980A2 (en) * 2008-09-12 2010-03-18 University Of South Florida Akt and clusterin as biomarkers of chemotherapeutic responsiveness
CA2756570C (en) 2009-04-17 2019-04-30 National Research Council Of Canada Peptide ligands for clusterin and uses thereof
CA2928846A1 (en) * 2009-11-24 2011-06-03 Alethia Biotherapeutics Inc. Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
CA2862739A1 (en) 2012-02-22 2013-08-29 Alethia Biotherapeutics Inc. Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer

Also Published As

Publication number Publication date
AU2013224591A1 (en) 2014-07-24
EP2817028A4 (en) 2015-11-04
CA2862739A1 (en) 2013-08-29
US9822170B2 (en) 2017-11-21
WO2013123588A1 (en) 2013-08-29
BR112014020756A2 (pt) 2017-07-04
US20150044220A1 (en) 2015-02-12
EA201491568A1 (ru) 2014-11-28
MX2014010164A (es) 2014-11-25
CN104159611A (zh) 2014-11-19
AU2013224591A9 (en) 2015-07-23
WO2013123588A9 (en) 2014-09-04
JP2015512877A (ja) 2015-04-30
EP2817028A1 (en) 2014-12-31

Similar Documents

Publication Publication Date Title
PH12016501384B1 (en) Human antibodies to pd-l1
MX2019004193A (es) Combinacion de anticuerpos anti-kir y anticuerpos anti-pd-1 para tratar cancer.
NZ741324A (en) Anti-cd47 antibodies and methods of use
NZ631197A (en) Anti sez6 antibodies and methods of use
TR201905909T4 (tr) Kanser tedavisi için anti-4-1bb antikorlarının ve adcc indükleyici antikorların kombinasyonları.
TR201812261T4 (tr) Pi3 ki̇naz i̇zoform modülatörleri̇ i̇le kanser tedavi̇si̇
NZ611785A (en) Anti-notch1 antibodies
JO3097B1 (ar) الأجسام المضادة c-Met
EA201190210A1 (ru) Ингибиторы связывания киназы с белком
MX2016004286A (es) Biomarcadores de cancer y usos de los mismos.
MX343227B (es) Anticuerpos anti-erbb3.
UA106070C2 (uk) Антитіло, що специфічно зв'язується з egfr і her3
HK1213924A1 (zh) 用於治療癌症的抗kir和抗ctla-4抗體組合
MX2013004761A (es) Nuevas moleculas de union al receptor del factor de crecimiento epidermico (egfr) e inmunoconjugados de estas.
EA201390575A1 (ru) Неантагонистические egfr-связывающие молекулы и их иммуноконъюгаты
MX2014014162A (es) Anticuerpos multiespecificos.
MX358728B (es) Composiciones de anticuerpos pan-receptor del factor de crecimiento epidermico humano (pan-her) humanizados.
BR112014024017A8 (pt) Métodos de tratamento de um tipo de câncer, de tratamento do carcinoma, para selecionar uma terapia e para quantificação e inibidor de her3
MX338185B (es) Uso de anticuerpos anti-egfr en el tratamiento de enfermedad mediada por egfr mutante.
MY186099A (en) Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
MX2016002051A (es) Metodos y kits para la subtipificacion molecular de tumores.
UA100969C2 (uk) Антитіло, яке специфічно зв'язує людський альфа5бета1 (alpha5beta1)
WO2011094335A3 (en) Microrna signatures predicting responsiveness to anti-her2 therapy
EP2579895A4 (en) ANTI-VEGF ANTIBODIES AND USES THEREOF
HK1247577A1 (zh) Egfr突变阳性的非小细胞肺癌的联合疗法

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 FEB 2018 BY FB RICE

Effective date: 20170215

LAPS Patent lapsed